Company news

Kamada Ltd. news in 2025

Kamada Ltd.'s news releases, calls and decks from 2025, newest first.

View company

Kamada Announces a $10-$14 Million Extension of Canadian Supply Tender

December 17, 2025

Kamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial; Reiterates 2025 Full-Year Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2026

December 7, 2025

Kamada Reports Strongest Quarter For The Year In Q3, With Over 30% Profitability Increase Year-Over-Year

November 18, 2025

Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability Growth

November 9, 2025

Kamada Announces First Patient Enrolled into an Investigator-Initiated Clinical Trial of CYTOGAM® to Prevent Cytomegalovirus in Kidney Transplantation

November 3, 2025

Kamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025

November 2, 2025

Kamada to Present at the Stifel 2025 Healthcare Conference

October 28, 2025

Kamada to Participate in Upcoming September Investor Conferences

September 1, 2025

Kamada Reports Strong Second Quarter and First Half 2025 Financial Results with 11% Year-Over-Year 6-Month Top Line Growth and a 35% Increase in Profitability; Raises Full-Year Profitability Guidance

August 12, 2025

Kamada Announces FDA Approval of its Plasma Collection Center in Houston, Texas

August 10, 2025

Kamada to Announce Second Quarter and First Half Ended June 30, 2025 Financial Results on August 13, 2025

August 5, 2025

Kamada Confirms Continuous Global Business Operations and Products Availability Despite Recent Events in the Middle East

June 16, 2025

Kamada Q1 Results: Double-Digit Growth, Company Reiterates Guidance As It Hits Multiple Milestones Including Plasma Business Expansion

June 10, 2025

Kamada Reports Strong First Quarter 2025 Financial Results with Year Over Year Top Line Growth of 17% and a 54% Increase in Profitability

May 13, 2025

Kamada to Announce First Quarter 2025 Financial Results on May 14, 2025

May 6, 2025

Kamada Announces Launch of a Comprehensive Post-Marketing Research Program for CYTOGAM®

May 4, 2025

Kamada Updates on Withholding Tax Procedures on Previously Announced Special Cash Dividend to Shareholders

March 23, 2025

Kamada Announces Expansion of Plasma Collection Operations with the Opening of New Site in San Antonio, Texas

March 18, 2025

Kamada Reports Record Top and Bottom Line 2024 Financial Results and Affirms 2025 Guidance Representing Double-Digit Profitable Growth

March 4, 2025

Kamada Declares Special Cash Dividend of $0.20 Per Share

March 4, 2025

Kamada to Announce Fourth Quarter and Fiscal Year 2024 Financial Results on March 5, 2025

February 25, 2025

Kamada Announces a $25 Million 3-Year Contract for Supply of KAMRAB® and VARIZIG® in Latin America

January 21, 2025

Kamada Affirms 2024 Financial Guidance and Announces Expected Continued Double-Digit Profitable Growth for 2025

January 7, 2025

Calls in 2025

Decks in 2025